Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells Summary Researchers have developed a directed evolution approach to discover ligands that can specifically restimulate chimeric antigen receptor (CAR) T Read More
Multiparametric cellular and spatial organization in cancer tissue lesions with a streamlined pipeline Summary This content focuses on analyzing cancer tissue using a comprehensive, multi-faceted approach. It combines cellular information (characteristics of individual cells) with Read More
Engineering B cells to treat and study human disease Summary Engineering B cells, the antibody-producing cells of the immune system, offers powerful tools for both treating and studying human diseases. Genetically modified B cells can Read More
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy Summary Nanobody-based bispecific antibody engagers offer a promising avenue for cancer immunotherapy. These molecules combine the target specificity of nanobodies, small and stable antibody Read More
Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses Summary Genetically engineered CAR-T cells can be modified to secrete bispecific killer cell engagers (BiKEs) targeting both tumor-associated antigens and NK Read More
Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia Summary Researchers have developed a bioengineered “trial-on-chip” system that mimics the human immune system to test CAR T-cell therapy effectiveness against Read More
Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody–STING agonist conjugates Summary This research explores a novel approach to enhance cancer immunotherapy by delivering STING (Stimulator of Interferon Genes) agonists directly to tumors using albumin-hitchhiking nanobody Read More
Hitchhiking albumin to STING tumours Summary Researchers have developed a novel drug delivery system targeting STING-activated tumors. By attaching a STING agonist (a drug that activates the STING pathway, boosting the immune response against cancer) Read More
1 Million+ Views and Counting..!
Now, it has been 6 years since it was launched in late July 2018 and is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
